A Phase II trial of PF-1804 for cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD)
Latest Information Update: 23 Mar 2026
At a glance
- Drugs Pemziviptadil (Primary)
- Indications Cardiomyopathies
- Focus Adverse reactions; Therapeutic Use
- Sponsors ImmunoForge
Most Recent Events
- 23 Mar 2026 New trial record